

Peripheral nerve injuries - Pipeline Insight, 2021

<https://marketpublishers.com/r/PB55B27B73C5EN.html>

Date: September 2021

Pages: 60

Price: US\$ 1,500.00 (Single User License)

ID: PB55B27B73C5EN

Abstracts

This report can be delivered to the clients within 48 hours

DelveInsight's, "Peripheral nerve injuries - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Peripheral nerve injuries pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Peripheral nerve injuries Understanding

Peripheral nerve injuries: Overview

Peripheral nerve injuries (PNI) include a variety of conditions in which one or more peripheral nerves are damaged. It leads to neurological deficits distal to the level of the lesion present. PNIs affect all age groups and damage to the peripheral nerves is known as peripheral neuropathy. The symptoms of PNI may vary depending on the nerve fiber affected and include pain in the affected area, burning sensations and numbness. The diagnosis of PNI involves a medical history, neurological examination, and, in some cases, diagnostic tests like x-ray if fracture is suspected, CT/MRI, or electrodiagnostic examination. Treatment for PNI depends on the injury and other external factors including early nerve exploration and repair. Nonsurgical treatments include medications, immobilization and physical therapy. Surgical treatment may be

needed if the individual has persistent neurologic symptoms.

'Peripheral nerve injuries - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Peripheral nerve injuries pipeline landscape is provided which includes the disease overview and Peripheral nerve injuries treatment guidelines. The assessment part of the report embraces, in depth Peripheral nerve injuries commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Peripheral nerve injuries collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Peripheral nerve injuries R&D. The therapies under development are focused on novel approaches to treat/improve Peripheral nerve injuries.

Peripheral nerve injuries Emerging Drugs Chapters

This segment of the Peripheral nerve injuries report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Peripheral nerve injuries Emerging Drugs

NTX-001: Neuraptive Therapeutics

NTX-001 is a combination drug-device product. NTX-001 has been developed as surgical product to be used in conjunction with standard suture neuroorrhaphy of a severed nerve in the U.S. via the FDA 505 (b) (2) development pathway. In May 2020, Neuraptive Therapeutics announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its therapeutic product, NTX-001, for the

treatment of patients with peripheral nerve injuries. The drug is in Phase II clinical studies for the treatment of peripheral nerve injuries.

ONO-2910: Ono Pharmaceutical

ONO-2910 promotes Schwann cell differentiation and myelination and is expected to improve various symptoms associated with peripheral neuropathy by protecting and promoting regeneration of peripheral nerve cells. The drug is currently under Phase II clinical development for the treatment of Peripheral nerve injuries.

Further product details are provided in the report.

Peripheral nerve injuries: Therapeutic Assessment

This segment of the report provides insights about the different Peripheral nerve injuries drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Peripheral nerve injuries

There are approx. 10+ key companies which are developing the therapies for Peripheral nerve injuries. The companies which have their Peripheral nerve injuries drug candidates in the most advanced stage, i.e. Phase II include, Neuraptive Therapeutics.

Phases

DelveInsight's report covers around 10+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Peripheral nerve injuries pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravitreal

Subretinal

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and

Mono/Combination.

Peripheral nerve injuries: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Peripheral nerve injuries therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Peripheral nerve injuries drugs.

Peripheral nerve injuries Report Insights

Peripheral nerve injuries Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Peripheral nerve injuries Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

How many companies are developing Peripheral nerve injuries drugs?

How many Peripheral nerve injuries drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Peripheral nerve injuries?

What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Peripheral nerve injuries therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Peripheral nerve injuries and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Neuraptive Therapeutics

MicroCures

SanBio

KannaLife Sciences

Sonnet BioTherapeutics

Ono Pharmaceutical

AxoGen

MedGenesis Therapeutix

Tetragenetics

Key Products

NTX-001

siFi2

SB 308

KLS-13019

Recombinant IL-6

ONO-2910

Avance Nerve Graft

SON-081

Liatermin

TTG-108

Contents

Introduction

Executive Summary

Peripheral nerve injuries: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Peripheral nerve injuries – DelveInsight's Analytical Perspective

Late Stage Products (Phase III)

Comparative Analysis

Drug name: Company name

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Mid Stage Products (Phase II)

Comparative Analysis

NTX-001: Neuraptive Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.

Early Stage Products (Phase I)

Comparative Analysis

Recombinant Interleukin-6: Sonnet Biotherapeutics Holdings

Product Description

Research and Development

Product Development Activities
Drug profiles in the detailed report.
Preclinical/Discovery Stage Products
Comparative Analysis
Liatermin: MedGenesis Therapeutix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report.
Inactive Products
Comparative Analysis
Peripheral nerve injuries Key Companies
Peripheral nerve injuries Key Products
Peripheral nerve injuries- Unmet Needs
Peripheral nerve injuries- Market Drivers and Barriers
Peripheral nerve injuries- Future Perspectives and Conclusion
Peripheral nerve injuries Analyst Views
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Peripheral nerve injuries
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Peripheral nerve injuries
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Peripheral nerve injuries - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/PB55B27B73C5EN.html>

Price: US\$ 1,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PB55B27B73C5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970